Literature DB >> 31625933

Palliative resection of primary site in advanced gastroenteropancreatic neuroendocrine tumors improves survivals.

Derya Kıvrak Salim1, Selami Bayram1, İsmail Gömceli2, Ayhan Hilmi Çekin3, Mustafa Karaca1, Murat Koçer1, Mustafa Yıldız1.   

Abstract

BACKGROUND/AIMS: Gastroenteropancreatic neuroendocrine tumors are rarely seen and have heterogeneous clinical outcomes. Mostly half of the patients had metastatic disease at presentation. Palliative resection of primary site in metastatic disease is still controversial. The aim of this study was to find out the influence of resection of primary tumor site on progression-free survival and overall survival in metastatic non-functioning gastroenteropancreatic neuroendocrine tumors. The secondary end point is to determine the prognostic factors influencing the survivals.
MATERIALS AND METHODS: This study was conducted at a single medical oncology center, Antalya Education and Research Hospital. Patients who had non-functioning metastatic gastroenteropancreatic neuroendocrine tumors with primary site resected or unresected were compared retrospectively. Resection of metastases was excluded.
RESULTS: Fifty-three patients were included in the study and 29 patients had primary tumor resection. The primary site resected group had favorable outcomes with the overall survival (median unreached) compared to the median overall survival of 30 months in the unresected group (p=0.001). Median progression-free survival was also better in the primary site resected group than the unresected group (60 months vs. 14 months, respectively) (p=0.013). In multivariate analysis, unresected primary site and high-grade tumors were found to be independent prognostic factors on low survivals (Hazard ratio (HR): 4.6; 95% CI: 1.21-17.47 and HR: 10.1; 95% CI: 1.15-88.84, respectively). Age (p=0.131), gender (p=0.051), chromogranin A level (p=0.104), Ki-67 index (p=0.550), tumor size (p=0.623), and primary tumor area (p=0.154) did not influence the overall survival.
CONCLUSION: Gastroenteropancreatic neuroendocrine tumors with primary site resected had improved survivals when compared to the unresected group.

Entities:  

Mesh:

Year:  2019        PMID: 31625933      PMCID: PMC6812952          DOI: 10.5152/tjg.2019.19168

Source DB:  PubMed          Journal:  Turk J Gastroenterol        ISSN: 1300-4948            Impact factor:   1.852


  19 in total

1.  ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site.

Authors:  M Pavel; D O'Toole; F Costa; J Capdevila; D Gross; R Kianmanesh; E Krenning; U Knigge; R Salazar; U-F Pape; K Öberg
Journal:  Neuroendocrinology       Date:  2016-01-05       Impact factor: 4.914

2.  Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival.

Authors:  Babak Givi; Suellen J Pommier; Alivia K Thompson; Brian S Diggs; Rodney F Pommier
Journal:  Surgery       Date:  2006-12       Impact factor: 3.982

3.  Outcomes of Cytoreductive Surgery for Metastatic Low-Grade Neuroendocrine Tumors in the Setting of Extrahepatic Metastases.

Authors:  David L Chan; Matthew Dixon; Calvin H L Law; Serge Koujanian; Kaitlyn A Beyfuss; Simron Singh; Sten Myrehaug; Julie Hallet
Journal:  Ann Surg Oncol       Date:  2018-03-20       Impact factor: 5.344

Review 4.  The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society.

Authors:  James R Howe; Kenneth Cardona; Douglas L Fraker; Electron Kebebew; Brian R Untch; Yi-Zarn Wang; Calvin H Law; Eric H Liu; Michelle K Kim; Yusuf Menda; Brian G Morse; Emily K Bergsland; Jonathan R Strosberg; Eric K Nakakura; Rodney F Pommier
Journal:  Pancreas       Date:  2017-07       Impact factor: 3.327

5.  Palliative resection of the primary tumor in 442 metastasized neuroendocrine tumors of the pancreas: a population-based, propensity score-matched survival analysis.

Authors:  Felix J Hüttner; Lutz Schneider; Ignazio Tarantino; Rene Warschkow; Bruno M Schmied; Thilo Hackert; Markus K Diener; Markus W Büchler; Alexis Ulrich
Journal:  Langenbecks Arch Surg       Date:  2015-07-22       Impact factor: 3.445

Review 6.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

7.  ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.

Authors:  M Falconi; B Eriksson; G Kaltsas; D K Bartsch; J Capdevila; M Caplin; B Kos-Kudla; D Kwekkeboom; G Rindi; G Klöppel; N Reed; R Kianmanesh; R T Jensen
Journal:  Neuroendocrinology       Date:  2016-01-05       Impact factor: 4.914

8.  Surgery in malignant pancreatic neuroendocrine tumors.

Authors:  Scott Q Nguyen; Luz P Angel; Celia M Divino; Stefanie Schluender; Richard R P Warner
Journal:  J Surg Oncol       Date:  2007-10-01       Impact factor: 3.454

9.  Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs).

Authors:  John K Ramage; A Ahmed; J Ardill; N Bax; D J Breen; M E Caplin; P Corrie; J Davar; A H Davies; V Lewington; T Meyer; J Newell-Price; G Poston; N Reed; A Rockall; W Steward; R V Thakker; C Toubanakis; J Valle; C Verbeke; A B Grossman
Journal:  Gut       Date:  2011-11-03       Impact factor: 23.059

10.  Resection of the Primary Gastrointestinal Neuroendocrine Tumor Improves Survival With or Without Liver Treatment.

Authors:  Aaron Lewis; Mustafa Raoof; Philip H G Ituarte; John Williams; Laleh Melstrom; Daneng Li; Byrne Lee; Gagandeep Singh
Journal:  Ann Surg       Date:  2019-12       Impact factor: 12.969

View more
  1 in total

1.  Resection of the Primary Tumor Improves the Survival of Patients With Stage IV Gastric Neuroendocrine Carcinoma.

Authors:  Zefeng Li; Hu Ren; Tongbo Wang; Xiaojie Zhang; Lulu Zhao; Chongyuan Sun; Penghui Niu; Chunguang Guo; Yingtai Chen; Dongbing Zhao
Journal:  Front Oncol       Date:  2022-07-14       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.